RxDoctor Payments Data

Diana Lim, MD

Internal Medicine · Bossier City, LANPI 1023047420

Payments from drug & device makers

$9,849in general payments, 2019–2025

Across 536 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Novo Nordisk$1K
  • AstraZeneca$835
  • Pfizer$679
  • Lilly USA, LLC$635
  • Esperion Therapeutics, Inc.$509
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$9,76499%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,849 in reported general payments places this provider in the 90th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$157,425
Medicare patients
288
Services billed
1,720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$115,248
MounjaroTirzepatide72$95,979
FarxigaDapagliflozin Propanediol115$87,616
RybelsusSemaglutide40$46,338
EliquisApixaban44$27,993
JanuviaSitagliptin Phosphate23$24,631
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$18,724
Repatha PushtronexEvolocumab17$12,313
NexlizetBempedoic Acid/Ezetimibe28$11,605
Repatha SureclickEvolocumab17$11,138
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog23$8,890
KerendiaFinerenone14$8,806
Tresiba Flextouch U-100Insulin Degludec15$7,343
Humalog Kwikpen U-200Insulin Lispro16$7,055
Icosapent Ethyl18$6,275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,344$161,586130 claims
Lilly USA, LLCMounjaro$635$95,97972 claims
AstraZenecaFarxiga$835$87,616115 claims
PfizerEliquis$679$27,99344 claims
MerckJanuvia$479$24,63123 claims
GSKTrelegy Ellipta$189$18,72418 claims
Esperion Therapeutics, Inc.Nexlizet$509$11,60528 claims
BayerKerendia$236$8,80614 claims
AbbVieSynthroid$231$2,27933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Bossier City

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →